BioNTech SE (BNTX) Receives a Buy from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...
BioNTech price target lowered to $147 from $150 at BofA
BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...
Moderna and BioNTech shares fall after Senate committee vote RFK Jr.
Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...
news.stocktradersdaily4d
(BNTX) Long Term Investment Analysis
Check the time stamp on this data. Updated AI-Generated Signals for Biontech Se (BNTX) available here: BNTX. Type a few ...
RFK Jr. HHS nomination advances out of Senate Finance Committee
The Senate Finance Committee advances the nomination of Robert F. Kennedy Jr. for HHS Secretary amid a party-line vote. Read ...
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of ...
Hosted on MSN2d
Moderna, BioNTech Shares Down After Senate Committee Vote To RFK Jr.’s Nomination
The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human ...
BioNTech fair value analysis yields 51% return in six months
Investing.com's Fair Value model demonstrated its effectiveness once again, identifying a significant opportunity in BioNTech SE (NASDAQ:BNTX) that resulted in a remarkable 51% return over just six ...
Autolus Therapeutics Will Remain Depressed For A While
Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.
Nasdaq6d
BioNTech SE American Depositary Share (BNTX) Analyst Research
This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...